<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01265667</url>
  </required_header>
  <id_info>
    <org_study_id>CF101-202PS</org_study_id>
    <nct_id>NCT01265667</nct_id>
  </id_info>
  <brief_title>Trial of CF101 to Treat Patients With Psoriasis</brief_title>
  <official_title>A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Efficacy and Safety of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Can-Fite BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Can-Fite BioPharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eligible patients with Psoriasis will be treated with CF101 or placebo twice daily for 16
      weeks. All subjects will receive open-lable CF101 in weeks 17-32.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients will be randomly assigned to parallel dosing groups of CF101 2 mg or
      matching placebo tablets twice daily (BID) in a 1:1 ratio for the 16-week controlled
      treatment period. Approximately 94 patients will be assigned to each group.

      Medication will be taken orally BID for 16 weeks in a double-blinded fashion. At the end of
      16 weeks, all patients assigned to CF101 will continue CF101, while patients originally
      assigned to placebo will be reassigned to CF101.

      Assessment of peripheral blood mononuclear cell (PBMC) adenosine A3 receptor (A3AR)
      expression at baseline and during treatment with CF101 in selected sites.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Achieving Psoriasis Area and Severity Index (PASI) 75 at 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>Achievement of PASI 75 indicates a 75% reduction in the PASI score, which ranges from 0 (no disease) to 72 (maximal disease)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Achieving PGA of 0 or 1</measure>
    <time_frame>16 weeks</time_frame>
    <description>PGA is a physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numberof Patients Achieving Psoriasis Area and Severity (PASI) Score of 50 or 75</measure>
    <time_frame>16 weeks</time_frame>
    <description>Achievement of PASI 50 or 75 indicates a 50% and 75% reduction respectively in the PASI score, which ranges from 0 (no disease) to 72 (maximal disease)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nature and Frequency of Adverse Events</measure>
    <time_frame>32 weeks</time_frame>
    <description>Assessment of safety of CF101 in this patient population by gathering adverse event data based on history, vital signs, physical examination, and laboratory data</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">293</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>CF101 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CF101</intervention_name>
    <description>orally q12h</description>
    <arm_group_label>CF101 2 mg</arm_group_label>
    <other_name>IB-MECA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>orally q12h</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Dummy pills</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18 to 80 years of age, inclusive

          -  Diagnosis of moderate-to-severe chronic plaque-type psoriasis with body surface area
             involvement ≥10%

          -  Duration of psoriasis of at least 6 months

          -  Physician global assessment (PGA) ≥3

          -  Candidate for systemic treatment or phototherapy for psoriasis

          -  Electrocardiogram (ECG) is normal

          -  Females of child-bearing potential must have a negative serum pregnancy test

          -  Females of child-bearing potential must be willing to use 2 methods of contraception

          -  Ability to complete the study in compliance with the protocol

          -  Ability to understand and provide written informed consent.

        Exclusion Criteria:

          -  Erythrodermic, guttate, palmar, plantar, or generalized pustular psoriasis

          -  Treatment with systemic retinoids, corticosteroids, or immunosuppressive agents within
             4 weeks of the Baseline visit

          -  Treatment with high potency topical corticosteroids, keratolytics, or coal tar within
             2 weeks of the Baseline visit

          -  Ultraviolet or Dead Sea therapy within 4 weeks of the Baseline visit

          -  Treatment with a biological agent within a period of time equal to 5 times its
             circulating half-life

          -  Treatment with lithium, hydroxychloroquine or chloroquine within 2 weeks of the
             Baseline visit

          -  Serum creatinine level greater than 1.5 times the laboratory's upper limit of normal

          -  Liver aminotransferase levels greater than the laboratory's upper limit of normal

          -  Significant acute or chronic medical or psychiatric illness

          -  Participation in another investigational drug or vaccine trial concurrently or within
             30 days prior to Screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael H Silverman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Can-Fite BioPharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;G.stranski&quot;</name>
      <address>
        <city>Pleven</city>
        <zip>5800,</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Tokuda hospital Sofia&quot;</name>
      <address>
        <city>Sofia,</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCC &quot;Fokus-5&quot;-MIOC, EOOD</name>
      <address>
        <city>Sofia,</city>
        <zip>1463</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Acdemy (MMA)</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Doverie&quot;</name>
      <address>
        <city>Sofia</city>
        <zip>1632,</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Center for Skin and Venereal Disease</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Ttreatment</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Varna at MMA Sofia</name>
      <address>
        <city>Varna,</city>
        <zip>9010,</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haemek Medical Center</name>
      <address>
        <city>Afula</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah Tiqva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrul Medical Euromed</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Dermato-Venerice</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency County Clinical Hospital</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Constanta</name>
      <address>
        <city>Constanta,</city>
        <zip>900622</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spit Clinic Judetean de Urgenta Sf Spiridon Iasi</name>
      <address>
        <city>Iasi</city>
        <zip>700368,</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>County Clinical Emergency Hospital</name>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Israel</country>
    <country>Romania</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.canfite.com/</url>
    <description>Can-Fite BioPharma website</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2010</study_first_submitted>
  <study_first_submitted_qc>December 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2010</study_first_posted>
  <results_first_submitted>June 1, 2017</results_first_submitted>
  <results_first_submitted_qc>August 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 20, 2017</results_first_posted>
  <last_update_submitted>August 20, 2017</last_update_submitted>
  <last_update_submitted_qc>August 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>Plaque psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CF101 2 mg</title>
          <description>CF101: orally q12h</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: orally q12h</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="145"/>
                <participants group_id="P2" count="148"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CF101 2mg</title>
          <description>Oral tablets given every 12 hours for 16 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Oral tablets given every 12 hours for 16 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="145"/>
            <count group_id="B2" value="148"/>
            <count group_id="B3" value="293"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.3" spread="13.57"/>
                    <measurement group_id="B2" value="50.0" spread="13.96"/>
                    <measurement group_id="B3" value="49.2" spread="13.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Achieving Psoriasis Area and Severity Index (PASI) 75 at 12 Weeks</title>
        <description>Achievement of PASI 75 indicates a 75% reduction in the PASI score, which ranges from 0 (no disease) to 72 (maximal disease)</description>
        <time_frame>12 weeks</time_frame>
        <population>Analysis was performed on the Intent-to-treat (ITT) Population</population>
        <group_list>
          <group group_id="O1">
            <title>CF101 2 mg</title>
            <description>CF101: orally q12h</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: orally q12h</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving Psoriasis Area and Severity Index (PASI) 75 at 12 Weeks</title>
          <description>Achievement of PASI 75 indicates a 75% reduction in the PASI score, which ranges from 0 (no disease) to 72 (maximal disease)</description>
          <population>Analysis was performed on the Intent-to-treat (ITT) Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Achieving PGA of 0 or 1</title>
        <description>PGA is a physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe)</description>
        <time_frame>16 weeks</time_frame>
        <population>Analysis was performed on the ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>CF101 2 mg</title>
            <description>CF101: orally q12h</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: orally q12h</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Achieving PGA of 0 or 1</title>
          <description>PGA is a physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe)</description>
          <population>Analysis was performed on the ITT population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Numberof Patients Achieving Psoriasis Area and Severity (PASI) Score of 50 or 75</title>
        <description>Achievement of PASI 50 or 75 indicates a 50% and 75% reduction respectively in the PASI score, which ranges from 0 (no disease) to 72 (maximal disease)</description>
        <time_frame>16 weeks</time_frame>
        <population>Analysis performed of the ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>CF101 2 mg</title>
            <description>CF101: orally q12h</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: orally q12h</description>
          </group>
        </group_list>
        <measure>
          <title>Numberof Patients Achieving Psoriasis Area and Severity (PASI) Score of 50 or 75</title>
          <description>Achievement of PASI 50 or 75 indicates a 50% and 75% reduction respectively in the PASI score, which ranges from 0 (no disease) to 72 (maximal disease)</description>
          <population>Analysis performed of the ITT population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nature and Frequency of Adverse Events</title>
        <description>Assessment of safety of CF101 in this patient population by gathering adverse event data based on history, vital signs, physical examination, and laboratory data</description>
        <time_frame>32 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CF101 2 mg</title>
            <description>CF101: orally q12h</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: orally q12h</description>
          </group>
        </group_list>
        <measure>
          <title>Nature and Frequency of Adverse Events</title>
          <description>Assessment of safety of CF101 in this patient population by gathering adverse event data based on history, vital signs, physical examination, and laboratory data</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections and infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal and connective tissue disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nervous system disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal and urinary disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 weeks</time_frame>
      <desc>All adverse events were collected and verbatim terms were coded via MedDRA dictionary</desc>
      <group_list>
        <group group_id="E1">
          <title>CF101 2 mg</title>
          <description>CF101: orally q12h</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: orally q12h</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="145"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Zivit Harpaz</name_or_title>
      <organization>Can-Fite BioPharma Ltd</organization>
      <phone>972-3-9241114</phone>
      <email>zivit@canfite.co.il</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

